Although the authors highlight the potential usefulness of GLP-1 RA treatment in neuromuscular diseases associated with atrophy, further studies are still needed to clearly determine the sarcopenic effect of GLP-1 RAs. This evidence concerns the gene GLP1R and neuromuscular disease.